arestin

· Next administration can be delivered ________ of the initial delivery

after (3) three months

DO NOT administer more than _________ to one particular site.

2 attempts

Arestin is ndicated in nonresponsive or recurrent pockets of ________ that continue to bleed upon probing.

5mm or greater

The patient must:

• be a patient of record who has had current debridement procedures.

•  return following the debridement procedures within a two-week period for tissue evaluation.

***Therapies other than LDAs should be considered when:

• Multiple sites with PD 75mm exist in the same quadrant.

  
  

• The use of LDAs has failed to control periodontitis (e.g., reduction of PD).

• Anatomical defects are present (e.g., intrabony defects).

At the two week tissue evaluation appointment the patient will be a candidate for Arestin if they meet the following criteria:

• the site must exhibit continued bleeding upon probing

  
  

• the site must have a probing depth over 5 mm

  
  

• an instructor must confirm the student's evaluation of the non responsive site(s).

  
  

• the patient must agree to return to the clinic in approximately four weeks to have the areas where Arestin was applied evaluated. The patient must sign a statement of this agreement on the treatment record prior to the Arestin placement.

After Arestin, Patient must return ________ to check tissue response.

after (4) four weeks

The patient must return within _______ for tissue evaluation after debridement procedure is complete to see if Arestin should be applied

(2) two weeks

ARESTIN® maintains therapeutic drug concentrations for _________

up to 21 days.